Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). METHODS: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 ± 18 with IBS diagnosed by Rome III criteria and with a score ≥ 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). FINDINGS: Open-label placebo produced significantly higher mean (±SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 ± 1.0 vs. 4.0 ± 1.1, p<.001) and at 21-day endpoint (5.0 ± 1.5 vs. 3.9 ± 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). CONCLUSION: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. TRIAL REGISTRATION: ClinicalTrials.gov NCT01010191.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The number-needed-to-treat was 11 which should be compared with 4 for ‘placebo without deception,259 7 for alosetron,260 8 for linaclotide261 and 14 for tegaserod.262”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Several trials of psychological treatments for IBS have failed to show differential effects on symptoms when using attention control conditions [32,62-64], and a recent study showed that IBS patients even respond to open-label placebo [65].”
The cited source says what the claim attributes to it.
In the citing paper
“Kaptchuk and colleagues showed that an open label inactive placebo pill produced better outcomes in IBS patients compared to no treatment13.”
From Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial (2014) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Collecting and Interpreting Qualitative Materials
Denzin, N. K., & Lincoln, Y. S. (2012) · Cited by 6,087
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 1×
“Participants were adults ($18 years old) meeting the Rome III criteria for IBS [17] with a score of $150 on the IBS Symptom Severity Scale (IBS-SSS).”
MethodFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“[18] The open-label group improved by 92 points on this measure; in addition, the improvement shown by the openlabel placebo group exceeded that shown by the no-treatment group by 46 points.”
MethodInfluentialIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384 · cited 1×
“[7,8] It is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits.”
BackgroundBiological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,272
Self-citationComponents of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
Kaptchuk, T. J., Kelley, J. M., Conboy, L. A., Davis, R. B., Kerr, C. E., Jacobson, E. E., Kirsch, I., Schyner, R. N., Nam, B. H., Nguyen, L. T., et al. (2008) · BMJ · doi:10.1136/bmj.39524.439618.25 · Cited by 1,196
Self-citationThe impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781 · cited 1×
“[9] The symptoms of IBS not only adversely affect a person’s health-related quality of life (QOL), [10,11] but are associated with a substantial financial burden of reduced work productivity and an over 50% increase in the use of health-related resources.”
BackgroundPlacebo interventions for all clinical conditions
Hróbjartsson, A., & Gøtzsche, P. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003974.pub3 · Cited by 777
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Camilleri, M., Northcutt, A. R., Kong, S., Dukes, G. E., McSorley, D., & Mangel, A. W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02033-x · Cited by 556 · cited 1×
“Finally, the percentage of patients reporting adequate relief during the preceding 7 days at the 21-day endpoint (59%) is comparable with the responder rates in clinical trials of drugs currently used in IBS.”
ResultThe epidemiology of irritable bowel syndrome in North America: a systematic review1
Saito, Y. A., Schoenfeld, P., & Locke, G. R. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05913.x · Cited by 548
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424 · cited 1×
“The IBS-QoL is a 34-item measure assessing the degree to which IBS interferes with patient quality of life. Each item is rated on a 5-point Likert scale and a linear transformation yields a summed score with a theoretical range of 0 to 100, with a higher score indicating better quality of life.”
BackgroundIntentional Ignorance: A History of Blind Assessment and Placebo Controls in Medicine
Kaptchuk, T. J. (1998) · Bulletin of the History of Medicine · doi:10.1353/bhm.1998.0159 · Cited by 314
Self-citationNovick, J., Miner, P., Krause, R., Glebas, K., Bliesath, H., Ligozio, G., Rüegg, P., & Lefkowitz, M. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01372.x · Cited by 289 · cited 1×
“[31,32] A recent meta-analysis of double-blind, placebo-controlled trials of alosetron in IBS estimated that 51% of patients treated with alosetron had adequate relief as compared to 38% of patients treated with placebo.”
MethodThe placebo effect in irritable bowel syndrome trials: a meta‐analysis1
Patel, S. M., Stason, W. B., Legedza, A., Ock, S. M., Kaptchuk, T. J., Conboy, L., Canenguez, K., Park, J. K., Kelly, E., Jacobson, E., et al. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00650.x · Cited by 285
Self-citationPrescribing "placebo treatments": results of national survey of US internists and rheumatologists
Tilburt, J. C., Emanuel, E. J., Kaptchuk, T. J., Curlin, F. A., & Miller, F. G. (2008) · BMJ · doi:10.1136/bmj.a1938 · Cited by 265
Self-citationThe Placebo Effect: Illness and Interpersonal Healing
Miller, F. G., Colloca, L., & Kaptchuk, T. J. (2009) · Perspectives in Biology and Medicine · doi:10.1353/pbm.0.0115 · Cited by 254 · cited 1×
“[1] Furthermore, recent studies have shown measurable”
Self-citationDrossman, D. A., Morris, C. B., Schneck, S., Hu, Y. J. B., Norton, N. J., Norton, W. F., Weinland, S. R., Dalton, C., Leserman, J., & Bangdiwala, S. I. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318189a7f9 · Cited by 235 · cited 3×
“[11,12] While many therapies are commonly used to treat individual IBS symptoms such as constipation or diarrhea, few therapies have been shown to be effective and safe in relieving the global symptoms of IBS.”
BackgroundAn Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225 · cited 1×
“[11,13] Previous research has demonstrated that placebo responses in IBS are substantial and clinically significant.”
BackgroundFässler, M., Meissner, K., Schneider, A., & Linde, K. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-15 · Cited by 211 · cited 2×
“As mentioned above, evidence indicates that physicians continue to use placebo treatment without transparent disclosure to patients [5,6] Our results suggest that the placebo response is not necessarily neutralized when placebos are administered openly.”
BackgroundParé, P., Gray, J., Lam, S., Balshaw, R., Khorasheh, S., Barbeau, M., Kelly, S., & McBurney, C. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.010 · Cited by 199 · cited 1×
“[11,12] While many therapies are commonly used to treat individual IBS symptoms such as constipation or diarrhea, few therapies have been shown to be effective and safe in relieving the global symptoms of IBS.”
BackgroundPark, L. C. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01720340008002 · Cited by 194
Lembo, T. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02690-9 · Cited by 192 · cited 2×
“Assessment Our primary outcome measure was the IBS Global Improvement Scale (IBS-GIS) which asks participants: ‘‘Compared to the way you felt before you entered the study, have your IBS symptoms over the past 7 days been: 1) Substantially Worse, 2) Moderately Worse, 3) Slightly Worse, 4) No Change, 5) Slightly Improve…”
MethodDiagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia
Hammer, J., Eslick, G. D., Howell, S. C., Altiparmak, E., & Talley, N. J. (2004) · Gut · doi:10.1136/gut.2003.021857 · Cited by 171 · cited 1×
“[19,20] was confirmed by a board certified gastroenterologist (AJL) or a nurse practitioner (EF) experienced in functional bowel disorders.”
BackgroundKaptchuk, T. J., Shaw, J., Kerr, C. E., Conboy, L. A., Kelley, J. M., Csordas, T. J., Lembo, A. J., & Jacobson, E. E. (2009) · Culture, Medicine, and Psychiatry · doi:10.1007/s11013-009-9141-7 · Cited by 158 · cited 1×
“[16] In view of these considerations, we selected IBS as a suitable condition to test the widespread belief that placebo responses are neutralized by awareness or knowledge that the treatment is a placebo.”
BackgroundSelf-citationThe Legitimacy of Placebo Treatments in Clinical Practice: Evidence and Ethics
Miller, F. G., & Colloca, L. (2009) · The American Journal of Bioethics · doi:10.1080/15265160903316263 · Cited by 156 · cited 1×
“[3] This belief creates an ethical conundrum: to be beneficial in clinical practice placebos require deception but this violates the ethical principles of respect for patient autonomy and informed consent.”
BackgroundSelf-citationOpen‐label use of placebos in the treatment of ADHD: a pilot study
Sandler, A. D., & Bodfish, J. W. (2008) · Child: Care, Health and Development · doi:10.1111/j.1365-2214.2007.00797.x · Cited by 147 · cited 1×
“[28] Our study suggests”
Park, L. C., & Covi, L. (1965) · PubMed · Cited by 147
Adequate Relief as an Endpoint in Clinical Trials in Irritable Bowel Syndrome
Mangel, A., Hahn, B., Heath, A., Northcutt, A., Kong, S., Dukes, G., & McSorley, D. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600203 · Cited by 143
Doctors, Patients, and Placebos.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-644_2 · Cited by 96
Gordon, S., Ameen, V. Z., Bagby, B., Shahan, B., Jhingran, P. M., & Carter, E. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1024159226274 · Cited by 90 · cited 2×
“Assessment Our primary outcome measure was the IBS Global Improvement Scale (IBS-GIS) which asks participants: ‘‘Compared to the way you felt before you entered the study, have your IBS symptoms over the past 7 days been: 1) Substantially Worse, 2) Moderately Worse, 3) Slightly Worse, 4) No Change, 5) Slightly Improve…”
MethodSituational factors contributing to the placebo effect
Gryll, S. L., & Katahn, M. (1978) · Psychopharmacology · doi:10.1007/bf00426747 · Cited by 89 · cited 1×
“[36,37] In our study, we found no evidence for significant differences between male physician and female nursepractitioner.”
BackgroundRahimi, R., Nikfar, S., & Abdollahi, M. R. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.002 · Cited by 80 · cited 1×
“A recent meta-analysis of double-blind, placebo-controlled trials of alosetron in IBS estimated that 51% of patients treated with alosetron had adequate relief as compared to 38% of patients treated with placebo.”
MethodDoctors, patients, and placebos
Bachrach, W. H. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90345-3 · Cited by 63
Morris, C. B., Hu, Y., Norton, W. F., Leserman, J., Drossman, D. A., Wanta, S. E., Bangdiwala, S. I., Dalton, C. B., Weinland, S. R., & Norton, N. J. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/h7nj-5334 · Cited by 34
Adequate relief as an endpoint in clinical trials in irritable bowel syndrome
Mangel, A. W., Hahn, B., Heath, A., Northcutt, A. R., Kong, S., Dukes, G. E., & McSorley, D. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)83255-1 · Cited by 11 · cited 1×
“The IBSAdequate Relief (IBS-AR) is a single dichotomous (yes or no) item that asks participants ‘‘Over the past week have you had adequate relief of your IBS symptoms?’’ [23] The IBS-QoL is a 34-item measure assessing the degree to which IBS interferes with patient quality of life.”
BackgroundSharp, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02032-8 · Cited by 7
Research works printed but not linked: 1
- Vanner SJ Depew WT Paterson WG 2004 Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome and functional dyspepsia. Gut 53 666 72 · DOI · Paper page
Cited by
RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH
Simon, L. S. (2012) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2012.678473 · Cited by 2,183
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
The neuroscience of placebo effects: connecting context, learning and health
Wager, T. D., & Atlas, L. Y. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3976 · Cited by 844
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
(2020) · doi:10.1056/nejmra1907805 · Cited by 634
Metadata
- Authors
- Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- National Institutes of Health (US)
- University of Hull (GB)
- Corresponding author
- Kaptchuk, Ted J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-22
- Volume
- 5
- Issue
- 12
- Pages
- e15591
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3008733
- OpenAlex
- W2105330971
- Semantic Scholar
- 3d8aac4fba0e556c2d0898ad83cd3df11576e90c
- Cited by
- 900
- References
- 43
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 48 · 2023: 56 · 2022: 55 · 2021: 67 · 2020: 72 · 2019: 55 · 2018: 97 · 2017: 48 · 2016: 55 · 2015: 55 · 2014: 65 · 2013: 48 · 2012: 58
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Bernard Osher Foundation
- National Institutes of Health (5r01at000402-04)
- Japan Society for the Promotion of Science (13J11021)
- National Center for Complementary and Alternative Medicine
- National Center for Complementary and Integrative Health (R01AT004662, K24AT004095, R01 AT00402-01)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
- Keywords
- irritable bowel syndrome, placebo effect, open-label placebo, symptom severity, quality of life, patient-provider interaction, informed consent
- MeSH terms
- Adult, Female, Humans, Deception, Male, Middle Aged, Placebos, Time Factors, Treatment Outcome, Patient Satisfaction, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

